Results 11 to 20 of about 75,785 (301)
CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch [PDF]
Frontiers in ImmunologyCD19 chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of relapsed/refractory B-cell malignancies, achieving high remission rates. Nonetheless, 20%-40% of patients eventually relapse, classified as either CD19+ or CD19− relapse.
Jiawen Huang, Xiaobing Huang, Duonan Yu
doaj +2 more sources
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting [PDF]
Molecular OncologyDevelopment of chimeric antigen receptor T‐cell therapy has revolutionized the treatment of B‐cell malignancies, although challenges such as antigen escape and tumor heterogeneity often decrease treatment success. Modular CARs targeting multiple antigens
Pablo Gonzalez‐Garcia +9 more
doaj +2 more sources
Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival [PDF]
Journal for ImmunoTherapy of CancerBackground Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22
Terry J Fry +5 more
doaj +2 more sources
Hematology, Transfusion and Cell Therapy, 2023 Introduction: The recent active use of immunotherapy based on CD19/CD3 bispecific T-cell engager (blinatumomab), brings significant problems on monitoring Minimal Residual Disease (MRD) based on Multiparameter Flow Cytometry (MFC), due to possible CD19 ...
RM Pontes +9 more
doaj +1 more source
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Cancer Cell International, 2021 Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li +11 more
doaj +1 more source
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. [PDF]
PLoS ONE, 2013 Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-tumor responses. Most infuse T cells genetically modified to express a chimeric antigen receptor (CAR) with specificity derived from the scFv region of a CD19 ...
Bipulendu Jena +6 more
doaj +1 more source
Blood Advances, 2023 Abstract Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cells that target 2 tumor antigens
Isabel Leung +11 more
openaire +2 more sources
Cells, 2022 Given the importance of B lymphocytes in inflammation and immune defense against pathogens, mice transgenic for Cre under the control of Cd19 promoter (Cd19Cre/+ mice) have been widely used to specifically investigate the role of loxP-flanked genes in B ...
Ying Zhao +9 more
doaj +1 more source
Nanobody based dual specific CARs [PDF]
, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +2 more sources
Antigen-specific cytokine profiles for pulmonary Mycobacterium avium complex disease stage diagnosis
Frontiers in Immunology, 2023 IntroductionControlling pulmonary Mycobacterium avium complex (MAC) disease is difficult because there is no way to know the clinical stage accurately. There have been few attempts to use cell-mediated immunity for diagnosing the stage.
Yoshiro Yamashita +16 more
doaj +1 more source